
    
      This is a double-blind, placebo-controlled, randomized, multiple-dose, single center study.
      36 male and female healthy subjects will be enrolled in this study. Within 14 days prior to
      study drug administration, subjects will be screened based on the inclusion and exclusion
      criteria. The study will be performed in 3 groups of 12 subjects each. In each group of 12
      subjects, 10 subjects will be randomly assigned to receive Hypidone Hydrochloride and 2
      subjects to receive matching placebo.
    
  